Drug Trial Radar · NCT05707208
A Randomized, Controlled Study of Repeat Dose Sustained Release Lidocaine for Treatment of Chronic Scrotal Pain
Last checked: Nov 19, 2026Latest source record: Mar 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
63
Actual
Start
Mar 21, 2023
Primary completion
Dec 4, 2025
Study completion Jan 21, 2026
Sponsor
- Lead sponsor
- Sustained Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 31, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multi-center, phase 2, randomized, single-blind, three-arm, active-controlled study is comparing repeat doses, every 28 days, of standard of care (SOC) plus ST-01 against SOC plus 1% lidocaine HCL in men experiencing chronic scrotal content pain (CSCP). The main purpose of this study is to determine if repeat injections of ST-01 are safe and effective in reducing pain. After completing a screening phase participants will be randomized into one of three groups: 1) ST-01 70 mg/mL arm, 2) ST-01 140 mg/mL arm, 3) 1% Lidocaine HCL arm (Control). Participants may receive up to 4 study treatment injections given at a minimum of 28-day intervals. Participants randomized to the Control arm will be given the opportunity to cross over to an ST-01 treatment arm after 2 study treatments.
Conditions
- Chronic Pain
Interventions
ST-01Drug
A sustained release lidocaine formulation designed for the treatment of acute and chronic pain.
1% Lidocaine HCLDrug
Currently approved lidocaine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Pain Scores on the Numerical Rating Scale (NRS) at 56 days.Time frame: 28 days after the second injection of ST-01 or 56 days after the first injection if only one study injection is received.
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Prostate Cancer Centre - Rockyview Hospital
Calgary, Alberta, Canada
Kelowna General Hospital Clinical Research Department
Kelowna, British Columbia, Canada
Vancouver Prostate Centre
Vancouver, British Columbia, Canada
Men's Health Clinic Manitoba
Winnipeg, Manitoba, Canada
Jonathan Giddens Medicine Professional Corporation
Brampton, Ontario, Canada
The Fe/Male Health Centre
Oakville, Ontario, Canada
Mount Sinai Hospital - Men's Health Institute
Toronto, Ontario, Canada
THEO Medical
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.